Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	113-52-0
Formula :	C₁₉H₂₅ClN₂
M.W :	316.87
SMILES Code :	CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.[H]Cl
Synonyms :	Imipramine (hydrochloride); Imipramine HCl; Melipramine
MDL No. :	MFCD00012669
InChI Key :	XZZXIYZZBJDEEP-UHFFFAOYSA-N
Pubchem ID :	8228

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

TgF344-AD rat primary neurons	1 μM	14 days	Evaluate the effect of Imipramine on pTau neuropathology, results showed Imipramine significantly reduced pTau neuropathology	PMC9241285
5xFAD mouse primary neurons	0.01, 0.1, 1.0 μM	9 days	Evaluate the effect of Imipramine on Aβ neuropathology, results showed Imipramine significantly reduced Aβ neuropathology	PMC9241285
Primary astrocytes	10 µM	24 h	Attenuated microglia-conditioned medium-induced astrocyte activation (GFAP/C3b downregulation) and ceramide (Cer) generation	PMC10440899
Primary microglia	10 µM	18 h	Inhibited Aβ oligomer-induced acid sphingomyelinase (A-SMase) activity and reduced proinflammatory cytokine (C1q, TNF-α, IL-1α) release	PMC10440899
colon epithelial Caco-2 cells	120 mg/L	30 and 90 min	Evaluate IMI's effect on Zn permeability; results showed enhanced Zn transcellular transport	PMC7551732
bovine ventricular muscle	0.01 μM to 50 μM	30 min	To study the effects of imipramine on action potential characteristics in bovine ventricular muscle. Results showed that imipramine at concentrations higher than 5 μM significantly decreased action potential amplitude, overshoot, and Vmax without affecting the resting membrane potential. Additionally, imipramine shortened both the action potential duration (APD) and the effective refractory period (ERP).	PMC2044363
bovine Purkinje fibres	0.01 μM to 50 μM	30 min	To study the effects of imipramine on action potential characteristics in bovine Purkinje fibres. Results showed that imipramine at concentrations higher than 1 μM significantly decreased action potential amplitude, overshoot, and maximum rate of depolarization (Vmax) without affecting the resting membrane potential. Additionally, imipramine decreased conduction velocity and altered membrane responsiveness and recovery time curves.	PMC2044363

C57BL/6 mice	Repeated Social Defeat (RSD) model	Drinking water administration	15mg/kg	Daily administration for 6 days	Imipramine diminished stress-induced inflammation in the periphery and central nervous system and related anxiety- and depressive- like behaviors.	PMC5010955
Female Lister hooded rats	Y-maze exploratory activity model	Intraperitoneal injection	10 mg/kg (first 3 days) and 2.5 mg/kg (4th day)	Once daily for 3 consecutive days, once on the 4th day	Imipramine pretreatment abolished naturally-occurring and drug-induced differences in exploratory activity, making rat behavior more uniform.	PMC2044328
Rats	Wistar rats	Subcutaneous injection	5 mg/kg	Once daily for 28 days	To investigate the effects of long-term imipramine treatment on m-CPP-induced suppression of locomotor activity and food intake. Results showed that long-term imipramine treatment enhanced the locomotor and food intake suppressant effects of m-CPP.	PMC1853590
5xFAD transgenic mice (Alzheimer’s disease model)	Alzheimer’s disease model	Intraperitoneal injection	15 µg/g	Once daily for 28 days	Reduced microglial/astrocytic activation, decreased GFAP/Cer/Aβ levels in brain-derived EVs, improved mitochondrial dysfunction, and ameliorated AD pathology (e.g., plaque deposition and neuronal death)	PMC10440899
Sprague-Dawley rats	Pilocarpine-induced seizure model	Intraperitoneal injection	10 mg/kg	Once weekly for four weeks	To evaluate the effects of imipramine on neuronal survival, oxidative stress, apoptosis, and cognitive function after seizures. Results showed that four weeks of imipramine treatment significantly increased hippocampal neuron survival, reduced oxidative stress marker 4HNE levels, decreased the Bax/Bcl-2 ratio, and improved spatial cognitive function.	PMC11853442
Sprague-Dawley rats	Severe hypoglycemia model	Intraperitoneal injection	10 mg/kg	Once per day for 7 days	To investigate the protective effects of imipramine on hypoglycemia-induced neuronal death. Results showed that imipramine significantly reduced hypoglycemia-induced hippocampal neuronal death and improved cognitive function.	PMC8869983
Wistar rats	Bipolar disorder model	Intraperitoneal injection	10 mg/kg	Once daily for 5 days	To investigate the effect of IMI administration in rats submitted to OUA-induced bipolar disorder model. Results showed that IMI elicited significant mania switch-like effect in OUA-treated animals.	PMC10485776
Male Albino Swiss mice	Forced swim test (FST) depression model	Oral (p.o.)	60 mg/kg	Single dose, 60 min before testing	Evaluate antidepressant efficacy and Zn redistribution; results demonstrated synergistic increase in brain Zn levels and BDNF/pCREB	PMC7551732
Rat	Rat caudate putamen	Oral	10 mg/kg	Twice a day for 14 days	To investigate the effect of prolonged imipramine treatment on the level of mRNA coding for D2 dopamine receptors in the rat caudate putamen, showing that repeated administration resulted in a significant increase in D2 dopamine receptor mRNA levels.	PMC1565237

{[proInfo.proName]}

CAS No.: 113-52-0

{[proInfo.proName]}

CAS No.: 113-52-0

Alternative Products

Product Details of Imipramine HCl

Safety of Imipramine HCl

Related Pathways of Imipramine HCl

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02191358	-		Completed	-	United States, California ... More >> Dr. Michael Dao Garden Grove, California, United States, 92844 United States, Colorado Kaiser Permanente Colorado Denver, Colorado, United States, 80011 United States, Kentucky Gill Heart Institute Lexington, Kentucky, United States, 40508 United States, Maryland IRC Clinics Towson, Maryland, United States, 21204 United States, Massachusetts Internal Medicine & Cardiology Associates Fall River, Massachusetts, United States, 02720 Prima CARE Fall River, Massachusetts, United States, 02720 United States, Virginia Carilion Clinic Christiansburg, Virginia, United States, 24073 Less <<
NCT00000464	Arrhythmia Ca... More >>rdiovascular Diseases Heart Arrest Heart Diseases Myocardial Infarction Ventricular Fibrillation Less <<	Phase 3	Completed	-	-
NCT00000518	Arrhythmia Ca... More >>rdiovascular Diseases Death, Sudden, Cardiac Heart Diseases Tachycardia, Ventricular Ventricular Arrhythmia Ventricular Fibrillation Less <<	Phase 3	Completed	-	-
NCT03599011	-		Not yet recruiting	September 2019	-
NCT01305707	Depression	Phase 4	Terminated(Difficulties in rec... More >>ruiting) Less <<	-	Spain ... More >> Hospital Universitari de Bellvitge Hospitalet de Llobregat, Barcelona, Spain, 08907 Corporació Sanitària Parc Tauli Sabadell, Barcelona, Spain, 08208 Hospital Universitari de Bellvitge, IDIBELL Barcelona, Spain, 08907 Less <<
NCT02653339	Rhinitis, Allergic, Perennial	Not Applicable	Unknown	August 2018	China, Beijing ... More >> Peking Union Medical College Hospital traditional Chinese medicine department Not yet recruiting Beijing, Beijing, China, 100730 Contact: Xiaoyang Zhang, Doctor (+86)13910769068 zhangxymz@163.com Less <<
NCT03220308	Attention Deficit Hyperactivit... More >>y Disorder Less <<	Not Applicable	Recruiting	December 2018	Netherlands ... More >> Karakter, Expertisecentrum voor kinder- en jeugdpsychiatrie Recruiting Arnhem, Gelderland, Netherlands, 6812DE Contact: Corina U Greven 0031646616038 c.greven@donders.ru.nl Contact: Nienke M Siebelink 0031646622594 n.siebelink@karakter.com Principal Investigator: Jan K Buitelaar Karakter, Expertisecentrum voor kinder- en jeugdpsychiatrie Recruiting Ede, Gelderland, Netherlands, 6717LX Contact: Corina U Greven 0031646616038 c.greven@donders.ru.nl Contact: Nienke M Siebelink 0031646622594 n.siebelink@karakter.com Karakter, Expertisecentrum voor kinder- en jeugdpsychiatrie Recruiting Nijmegen, Gelderland, Netherlands, 6525GC Contact: Corina U Greven 0031646616038 c.greven@donders.ru.nl Contact: Nienke M Siebelink 0031646622594 n.siebelink@karakter.com Principal Investigator: Jan K Buitelaar Less <<
NCT00704860	Major Depression	Phase 4	Completed	-	Canada, Ontario ... More >> University of Ottawa Institute of Mental Health Research Ottawa, Ontario, Canada, K1Z 7K4 Less <<
NCT02374567	Dementia Depr... More >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders Less <<	Phase 3	Terminated	-	Germany ... More >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany Less <<
NCT03055468	Diabetes Mellitus ... More >> Depression Less <<	Not Applicable	Not yet recruiting	March 30, 2018	-
NCT01944657	1. Major Depressive Disorder	Not Applicable	Withdrawn(unable to enroll sub... More >>jects) Less <<	December 2015	United States, Maryland ... More >> Sheppard Pratt Health System Towson, Maryland, United States, 21204 Less <<
NCT00000504	Arrhythmia Ca... More >>rdiovascular Diseases Heart Diseases Ventricular Arrhythmia Less <<	Phase 2	Completed	-	-
NCT03545399	Anhedonia in Healthy Volunteer... More >>s Less <<	Not Applicable	Completed	-	-
NCT03548675	Depressive Disorder, Major	Phase 4	Recruiting	May 2021	Netherlands ... More >> Radboudumc Dept of Psychiatry Recruiting Nijmegen, Netherlands, 6500 HB Contact: Joost Janzing, MD, PhD 0031243666495 Joost.janzing@radboudumc.nl Less <<
NCT01896349	Treatment Resistant Depression	Not Applicable	Unknown	November 2014	Brazil ... More >> Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA) Recruiting Porto Alegre, RS, Brazil, 90035-003 Contact: Lívia H Souza, MD +55 5198658701 livia.hs@terra.com.br Contact: Marcelo PA Fleck, MD, PhD +55 51 33598294 mfleck.voy@terra.com.br Sub-Investigator: Lívia H Souza, MD Principal Investigator: Marcelo PA Fleck, MD, PhD Sub-Investigator: Marco Antonio K Caldieraro, MD, MSc Sub-Investigator: Lucas Spanemberg, MD Sub-Investigator: Edgar A Vares, MD Less <<
NCT00944996	Major Depression	Not Applicable	Completed	-	Israel ... More >> Tirat Carmel Mental Health Center Tirat Hacarmel, Israel, 30200 Less <<
NCT01028014	-		Completed	-	-
NCT01028014	Urethral Sphincter Activity	Not Applicable	Completed	-	United States, Alabama ... More >> University of Alabama at Birmingham, The Kirklin Clinic Birmingham, Alabama, United States, 35233 Less <<
NCT01179828	Low Back Pain	Phase 3	Completed	-	Switzerland ... More >> Andreas Siegenthaler Dep. of Anesthesiolgy and Pain therapy, Bern University Hospital, Switzerland, 3010 Bern Less <<
NCT00227955	Depression	Phase 4	Completed	-	United States, Pennsylvania ... More >> Western Psychiatric Institute and Cinic Pittsburgh, Pennsylvania, United States, 15213 Less <<
NCT00004834	Panic Disorder	Not Applicable	Completed	-	-
NCT00404755	-		Completed	-	-
NCT00296777	Major Depression ... More >> Dysthymia Less <<	Phase 4	Completed	-	United States, New York ... More >> Depression Evaluation Service - New York State Psychiatric Institute New York, New York, United States, 10032 Less <<
NCT00404755	Major Depressive Disorder ... More >> Dysthymia Less <<	Phase 4	Completed	-	United States, New York ... More >> New York State Psychiatric Institute New York, New York, United States, 10032 Less <<
NCT00296725	Major Depression ... More >> Dysthymia Depressive Disorder NOS Less <<	Phase 4	Completed	-	United States, New York ... More >> Depression Evaluation Service, New York State Psychiatric Institute New York, New York, United States, 10032 Less <<
NCT00005575	Chest Pain	Phase 3	Completed	-	United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 Less <<
NCT00000390	Depression	PHASE2	COMPLETED	-	New York Hosp - Cornell Med Ct... More >>r, New York, New York, 10021, United States Less <<
NCT00206999	Healthy Volunteers	Not Applicable	Completed	-	Denmark ... More >> Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup Glostrup, Denmark, DK-2600 Less <<
NCT01518634	Somatisation Disorder ... More >> Somatoform Disorders Less <<	Phase 2	Completed	-	Denmark ... More >> Research Clinic for Functional Disorders Aarhus, Denmark, 8000 Less <<
NCT01753128	Gastroesophageal Reflux Diseas... More >>e Less <<	Phase 3	Completed	-	Thailand ... More >> Medical Institue; Siriraj Hospital Bangkok, Thailand, 10700 Less <<
NCT00164775	Functional Gastrointestinal Di... More >>sorder Less <<	Phase 3	Completed	-	Hong Kong ... More >> Prince of Wales Hospital Hong Kong, Hong Kong Less <<
NCT03122444	Breast Cancer	Not Applicable	Not yet recruiting	December 2021	-
NCT01107353	Depression	Not Applicable	Completed	-	United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042-4712 Less <<
NCT01047488	Polyneuropathy	Phase 4	Unknown	March 2013	Denmark ... More >> Department of Neurology, Aalborg Hospital Not yet recruiting Aalborg, Denmark, DK-9000 Contact: Flemming W. Bach, MD +45 99321928 fwb@rn.dk Principal Investigator: Flemming W. Bach, MD Department of Neurology, Odense University Hospital Not yet recruiting Odense, Denmark, DK-5000 Contact: Søren H. Sindrup, MD +45 65412471 soeren.sindrup@ouh.regionsyddanmark.dk Contact: Jakob V. Holbech, MD Holbech@dadlnet.dk Principal Investigator: Søren H. Sindrup, MD Principal Investigator: Jakob V. Holbech, MD Department of Neurology, Aarhus University Hospital Not yet recruiting Århus, Denmark, DK-8000 Contact: Troels S. Jensen, MD +45 89494137 tsjensen@ki.au.dk Contact: Nanna Finnerup, MD finnerup@ki.au.dk Principal Investigator: Troels S. Jensen, MD Sub-Investigator: Nanna Finnerup, MD Less <<
NCT01107353	-		Completed	-	-
NCT03102645	Urinary Incontinence, Stress ... More >> Fecal Incontinence Less <<	Phase 1	Completed	-	Denmark ... More >> Zelo Phase I Unit, Dept. of Clinical Pharmacology, Bispebjerg Hospital Copenhagen, Copenhagen NV, Denmark, 2400 Less <<
NCT00946764	Depression	Phase 1	Completed	-	-
NCT00693680	Major Depression	Not Applicable	Completed	-	Poland ... More >> Department of Psychiatry, Collegium Medicum, Jagiellonian University Krakow, Poland, 31-501 Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed